Core Insights - Nexalin Technology, Inc. has appointed Dr. Robert Rothstein to its Scientific Advisory Board, enhancing its focus on addressing the global mental healthcare crisis, particularly in Alzheimer's disease and Traumatic Brain Injury (TBI) [1][3] Company Developments - Dr. Rothstein brings over 40 years of experience in emergency medicine and mental health, having held senior roles at institutions like the University of Chicago and Johns Hopkins Medicine, which positions him well to support Nexalin's neuropsychiatric therapeutic initiatives [2][4] - The expansion of the Scientific Advisory Board follows a reconstitution in May 2025, aligning with Nexalin's intensified focus on Alzheimer's disease and TBI, with plans to initiate Alzheimer's-specific trials in Q4 2025 [3][5] Strategic Focus - Nexalin's DIFS™ technology is believed to stimulate deep brain regions linked to memory and executive function, with ongoing research suggesting its potential benefits for TBI recovery, especially in military populations [3][5] - The company aims to leverage robust imaging biomarkers and MEG-guided protocols to support its clinical trials, ensuring rigorous oversight from the Scientific Advisory Board [5] Industry Context - The company is positioned at the intersection of bioelectronic medicine and unmet neuropsychiatric needs, with Dr. Rothstein expressing enthusiasm for the non-invasive nature of Nexalin's technology in treating Alzheimer's and TBI [4]

HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries. Attendees will have the opportunity t ...

Nexalin Technology Inc. (NASDAQ:NXL) stock spiked on Wednesday, with a massive session volume of 167.9 million compared to the average volume of 972.2 thousand, as per data from Benzinga Pro.The company announced the publication of additional positive clinical data in Radiology demonstrating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS technology—Nexalin’s advanced implementation of transcranial alternating current stimulation (tACS)—improves cognitive performance and enhances brain network conn ...

Core Insights - Nexalin Technology, Inc. has published positive clinical data demonstrating that its Gen-2 Nexalin DIFS™ technology significantly improves cognitive performance and brain connectivity in patients with mild Alzheimer's disease, marking a significant milestone for the company's technology platform [1][2] Clinical Study Findings - The study is the first to provide fMRI confirmation that a 40-Hz, 15 mA electrical waveform can enhance hippocampal-cortical connectivity in Alzheimer's patients, correlating with measurable cognitive improvements [2] - Patients using Nexalin's Gen-2 SYNC 40-Hz DIFS device showed statistically significant improvements in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores compared to the sham group, with P-values of .001 and .03 respectively [5] - Enhanced functional connectivity was observed between the hippocampus and key cortical regions, critical for memory and executive function, as confirmed by resting-state fMRI [5] - Increased connectivity between the hippocampus and middle cingulate gyrus was significantly correlated with improvements on the Boston Naming Test, indicating a link between brain network modulation and cognitive outcomes [5] Safety and Regulatory Status - The Nexalin Gen-2 SYNC 15 mA DIFS device has been approved in China for treating depression and insomnia, and in Brazil and Oman for anxiety, depression, and insomnia [3][6] - No adverse events were reported during the treatment period, reinforcing the safety and tolerability of Nexalin's DIFS technology [5] Market Potential - The global Alzheimer's disease market is projected to exceed $20 billion annually, highlighting the potential for Nexalin's non-invasive neurostimulation technology as a safe and effective alternative to pharmacologic treatments [2]

HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Design Patent No. D1,092,758, entitled Transcranial Electro-Stimulation Device, providing 15 years of design protection for the Company’s next-generation HALO™ Clarity neuromodulation device. HALO™ Clarity is designed to ...

Accessibility StatementSkip Navigation SYDNEY, Sept. 17, 2025 /PRNewswire/ -- Nuix ('the Company', ASX: NXL) today announces it has won a multiyear contract to supply forensic analysis software to the tax authority of German state Rhineland-Palatinate (Landesamt für Steuern Rheinland-Pfalz). Nuix Neo automates workflows, ingesting data from over 1,000 file types at scale. Using responsible AI, advanced automation, and deep link-analysis, the software enables investigators to uncover the truth in vast, compl ...

Core Insights - Nexalin Technology, Inc. is hosting a webinar on September 9, 2025, to discuss its innovative approach to mental healthcare using its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology [1][2] - The company is positioned in a $537 billion mental health market, with international regulatory approvals and U.S. expansion plans underway [2] - Nexalin's technology includes real-time AI-driven patient monitoring and aims to provide scalable, at-home treatment options through its Gen-3 HALO™ Clarity headset and Virtual Clinic model [2] Company Overview - Nexalin Technology, Inc. designs and develops non-invasive neurostimulation products aimed at addressing the global mental health epidemic [4] - The company's devices are believed to penetrate deep brain structures associated with mental health disorders, potentially enhancing patient response without adverse side effects [4] - The Nexalin Gen-2 15 milliamp neurostimulation device has received regulatory approval in China, Brazil, and Oman [4]

PART I. FINANCIAL INFORMATION [Item 1. Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=ITEM%201.%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Unaudited Q2 2025 financials reveal a net loss and negative cash flow, offset by increased equity from a recent stock offering [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Item | June 30, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $431,320 | $574,485 | | Short-term investments | $5,361,465 | $2,905,438 | | Total Current Assets | $6,269,111 | $3,961,141 | | Total Assets | $6,563,982 | $4,222,732 | | **Liabilities & Equity** | | | | Total Current Liabilities | $600,584 | $546,694 | | Total Liabilities | $600,584 | $546,694 | | Total Stockholders' Equity | $5,963,398 | $3,676,038 | - Total assets increased significantly to **$6.56 million** from **$4.22 million**, primarily driven by a rise in short-term investments following a stock offering[11](index=11&type=chunk) - Total stockholders' equity grew to **$5.96 million** from **$3.68 million**, reflecting the net proceeds from the recent equity issuance, partially offset by the accumulated deficit[11](index=11&type=chunk) [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Summary (Unaudited) | Metric | Three Months Ended June 30, 2025 ($) | Three Months Ended June 30, 2024 ($) | Six Months Ended June 30, 2025 ($) | Six Months Ended June 30, 2024 ($) | | :--- | :--- | :--- | :--- | :--- | | Revenues, net | $70,588 | $26,840 | $111,603 | $105,511 | | Gross profit | $47,750 | $19,593 | $75,207 | $89,108 | | Total operating expenses | $1,668,608 | $1,316,614 | $3,707,290 | $2,459,841 | | Loss from operations | $(1,620,858) | $(1,297,021) | $(3,632,083) | $(2,370,733) | | Net loss | $(1,580,987) | $(1,284,493) | $(3,569,324) | $(2,325,650) | | Net loss per share (Basic & Diluted) | $(0.10) | $(0.17) | $(0.25) | $(0.31) | - Revenues for Q2 2025 more than doubled year-over-year, reaching **$70.6 thousand**, while revenues for the six-month period showed modest growth[13](index=13&type=chunk) - Operating expenses increased significantly for both the three and six-month periods, leading to wider net losses compared to the prior year[13](index=13&type=chunk) [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) - Stockholders' equity increased from **$3.68 million** on January 1, 2025, to **$5.96 million** on June 30, 2025[15](index=15&type=chunk) - The primary driver for the increase in equity was the issuance of 4,090,000 shares as part of an offering, which contributed approximately **$4.65 million** in additional paid-in capital[15](index=15&type=chunk) - The increase from the stock issuance was partially offset by a net loss of **$3.57 million** for the six-month period[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary for the Six Months Ended June 30 (Unaudited) | Cash Flow Activity | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | $(2,343,379) | $(2,009,704) | | Net cash provided by (used in) investing activities | $(2,446,183) | $2,278,270 | | Net cash provided by financing activities | $4,646,397 | $0 | | **Net (decrease) increase in cash** | **$(143,165)** | **$268,566** | - Financing activities provided **$4.65 million** in cash during the first six months of 2025, entirely from the sale of common stock, compared to zero in the same period of 2024[18](index=18&type=chunk) - Cash used in operations increased to **$2.34 million**, reflecting the larger net loss during the period[18](index=18&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes provide critical context to the financial statements, covering business operations, liquidity, accounting policies, and key financial items [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=ITEM%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management highlights new device development, Q2 2025 revenue growth, increased losses from R&D, and expresses substantial doubt about the company's going concern - The company's strategy is focused on developing its new Gen-2 SYNC and Gen-3 HALO neurostimulation devices, which use a more powerful **15 milliamp** waveform, and navigating the FDA regulatory process for U.S. market entry[118](index=118&type=chunk)[119](index=119&type=chunk) - Sales of the older Gen-1 device **remain paused** in the U.S. following an FDA reclassification in 2019, though the company continues to derive some revenue from legacy units[117](index=117&type=chunk) - The company is developing a virtual clinic platform to allow physicians to prescribe and monitor the Gen-3 HALO headset for at-home patient use, aiming to address the stigma associated with traditional mental health treatments[131](index=131&type=chunk) - Recent international progress includes **regulatory approval** for the Gen-2 device in Brazil and operational use in Oman[138](index=138&type=chunk)[139](index=139&type=chunk) [Results of Operations](index=30&type=section&id=Results%20of%20Operations) Comparison of Three Months Ended June 30, 2025 and 2024 | Metric | 2025 ($) | 2024 ($) | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Revenues, net | $70,588 | $26,840 | $43,748 | 163% | | Gross profit | $47,750 | $19,593 | $28,157 | 144% | | Total operating expenses | $1,668,608 | $1,316,614 | $351,994 | 27% | | Net loss | $(1,580,987) | $(1,284,493) | $(296,494) | 23% | - The **163%** increase in Q2 2025 revenue was primarily due to a large shipment of boards to China[141](index=141&type=chunk) - The **27%** increase in Q2 2025 operating expenses was driven by higher stock-based compensation (**~$260 thousand**), increased consulting expenses (**~$50 thousand**), and higher R&D costs for clinical trials[143](index=143&type=chunk)[145](index=145&type=chunk)[146](index=146&type=chunk) - For the six months ended June 30, 2025, the net loss widened by **53%** to **$3.6 million**, largely due to a **$740.0 thousand** increase in stock-based compensation and a **$357.0 thousand** increase in R&D expenses[149](index=149&type=chunk)[153](index=153&type=chunk)[154](index=154&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) - As of June 30, 2025, the company had approximately **$431.0 thousand** in cash and cash equivalents and **$5.4 million** in short-term investments[162](index=162&type=chunk) - The company has a significant accumulated deficit of **$88.2 million** and negative operating cash flows of **$2.3 million** for the first six months of 2025[162](index=162&type=chunk) - Management has concluded that the company will not have sufficient cash to satisfy its anticipated cash requirements for the next twelve months, which raises **substantial doubt about its ability to continue as a going concern**[163](index=163&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=37&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, Nexalin is not required to provide the information for this item - The company is **not required to provide this information** as it qualifies as a smaller reporting company[178](index=178&type=chunk) [Item 4. Controls and Procedures](index=37&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were ineffective due to material weaknesses in internal control over financial reporting - Management identified **material weaknesses** in internal control over financial reporting[179](index=179&type=chunk) - The identified weaknesses include: (i) lack of sufficient resources for adequate segregation of duties in financial reporting, and (ii) insufficient IT controls related to user access to the financial reporting system[179](index=179&type=chunk) - Due to these weaknesses, management concluded that disclosure controls and procedures were **not effective** as of the end of the period[180](index=180&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=39&type=section&id=ITEM%201.%20Legal%20Proceedings) The company reports no material pending legal proceedings - There are **no material pending legal proceedings** involving the company[184](index=184&type=chunk) [Item 1A. Risk Factors](index=39&type=section&id=ITEM%201A.%20Risk%20Factors) The company reports a new risk factor related to U.S. trade policy changes and tariffs, which could adversely affect business with China - A new risk factor has been added regarding recent changes to U.S. trade policy, including tariffs, which could adversely affect the business[186](index=186&type=chunk) - Ongoing trade tensions between the U.S. and China could harm sales and operations by impacting the importation of products or subjecting the company's exports to retaliatory tariffs[188](index=188&type=chunk)[189](index=189&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=ITEM%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities or use of proceeds from registered securities for the period - **None reported for the period**[190](index=190&type=chunk) [Item 6. Exhibits](index=40&type=section&id=ITEM%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including material contracts and corporate governance documents - The report lists numerous exhibits, including the Underwriting Agreement from the May 2025 offering, the Joint Venture Agreement with Wider Come Limited, and various employment and consulting agreements[195](index=195&type=chunk)

Core Insights - Nexalin Technology, Inc. has appointed Justin Van Fleet as Chief Financial Officer effective August 1, 2025, bringing over 20 years of experience in public accounting and assurance services [1][2] - Mr. Van Fleet has a strong track record in financial systems development, regulatory compliance, and strategic financial management, particularly in guiding companies through complex financial transactions [2][3] - The company is at a pivotal moment with its innovative neurostimulation technology aimed at treating serious mental health conditions, and Mr. Van Fleet's expertise will be crucial for scaling operations and advancing the technology [4] Company Overview - Nexalin Technology designs and develops non-invasive neurostimulation products to address the global mental health epidemic, utilizing bioelectronic medical technology [6] - The company's Generation 2 and Generation 3 devices are currently under FDA review and are designed to provide deep-brain stimulation without drugs or invasive procedures, targeting conditions such as anxiety and depression [4][6] - Nexalin's Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman, indicating its potential for international market expansion [6]

Core Insights - Nexalin Technology, Inc. is hosting a webinar on June 3, 2025, to discuss its innovative approach to mental healthcare using its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology [1][2] - The company is positioned in a $537 billion mental health market, with international regulatory approvals and U.S. expansion plans underway [2] - Nexalin's technology includes real-time AI-driven patient monitoring and aims to provide scalable, at-home treatment options [2] Company Overview - Nexalin designs and develops non-invasive neurostimulation products aimed at addressing the global mental health epidemic [4] - The company's devices are believed to penetrate deep brain structures associated with mental health disorders, enhancing patient response without adverse side effects [4] - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman [4]